The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01589705
Recruitment Status : Terminated (Patients recruitment and analysis were terminated)
First Posted : May 2, 2012
Last Update Posted : July 31, 2012
Information provided by (Responsible Party):
Ismail Kocyigit, TC Erciyes University

Brief Summary:
There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level and endothelial dysfunction has not been elucidated yet in these patients. Therefore, in this study, the investigators aimed to examine the relationship between the uric acid level and the ED in normotensive ADPKD patients with preserved renal function.

Condition or disease
Polycystic Kidney, Autosomal Dominant

Detailed Description:
This is the first study to evaluate the relationship between uric acid and endothelial dysfunction in patients with early stage ADPKD

Study Type : Observational
Actual Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Endothelial Dysfunction in Patients With Polycystic Kidney Disease
Study Start Date : January 2012
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
Drug Information available for: Uric Acid

polycystic kidney ,no hypertension
The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function

Primary Outcome Measures :
  1. Measurement of asymmetric dimethylarginine (ADMA) and flow mediated dilatation (FMD) [ Time Frame: 4 months ]
    ADMA,FMD and uric acid measurements were performed to determine endothelial dysfunction in ADPKD patients

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with early stage(preserved renal function) Autosomal dominant polycystic kidney disease (n = 91) from two academic medical center.We also excluded the patients with a previous diagnosis of hypertension, gout, diabetes, current use of oral antidiabetic medication, insulin, thiazide, allopurinol or uricosuric, or a fasting glucose level 126 mg/dl. In addition, the subjects with a history of smoking or current use of any anti-hypertensive medication and statins were excluded

Inclusion Criteria:

  • ADPKD patients with normal renal function,
  • Normotensive ADPKD patients

Exclusion Criteria:

  • Patients with impaired kidney function,
  • Atherosclerotic disorders,
  • Diagnosis of hypertension, gout, diabetes,
  • Using of insulin, thiazide, allopurinol or uricosuric drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01589705

Erciyes University Medical School
Kayseri, Turkey, 38039
Sponsors and Collaborators
TC Erciyes University
Study Director: Bulent Tokgoz, Professor Erciyes University Medical School

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ismail Kocyigit, TC Erciyes University Medical School, TC Erciyes University Identifier: NCT01589705     History of Changes
Other Study ID Numbers: Erciyes 2011/273
First Posted: May 2, 2012    Key Record Dates
Last Update Posted: July 31, 2012
Last Verified: July 2012

Keywords provided by Ismail Kocyigit, TC Erciyes University:
Uric acid
polycystic kidney disease

Additional relevant MeSH terms:
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Kidney Diseases
Urologic Diseases
Kidney Diseases, Cystic
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
Uric Acid
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs